<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03454945</url>
  </required_header>
  <id_info>
    <org_study_id>doxycycline</org_study_id>
    <nct_id>NCT03454945</nct_id>
  </id_info>
  <brief_title>Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides</brief_title>
  <official_title>Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current study aims at assessing the efficacy of doxycycline as a potential treatment modality&#xD;
      for early stages of MF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
      Objective is to evaluate the efficacy of doxycycline in treatment of early stages of mycosis&#xD;
      fungoides (IA, IB and IIA) and to assess its apoptotic enhancing effect by studying the&#xD;
      expression of BCL2 by the T lymphocytes.&#xD;
&#xD;
      Study Design&#xD;
&#xD;
      Randomized controlled trial&#xD;
&#xD;
      Population of study &amp; disease condition&#xD;
&#xD;
      30 patients with early stage mycosis fungoides (Stage Ia,Ib and IIa)&#xD;
&#xD;
      Methodology in details&#xD;
&#xD;
      After signing an informed consent, each participant will be subjected to:&#xD;
&#xD;
      I. Baseline evaluation:&#xD;
&#xD;
        1. Baseline biopsy to document the current state of the disease and to assess&#xD;
           immunohistochemically the expression of CD3 and Bcl2 by the lymphocytes.&#xD;
&#xD;
        2. Detailed history taking including onset, course, duration of the disease and history of&#xD;
           any previous treatments used.&#xD;
&#xD;
        3. Detailed examination of skin lesions and scoring using:&#xD;
&#xD;
             -  Modified Severity of Index Weighted Assessment (mSWAT)&#xD;
&#xD;
             -  Composite Assessment of Index Lesion Severity (CAILS)&#xD;
&#xD;
        4. Pruritus scoring using a visual analog scale from 0-10, where 0=no pruritus and 10=worst&#xD;
           imaginable pruritus&#xD;
&#xD;
        5. Photography&#xD;
&#xD;
      II. Treatment and dosing protocol:&#xD;
&#xD;
      Participants will be randomly allocated in either one of the treatment groups:&#xD;
&#xD;
      Group A: Will receive oral doxycycline in a dose of 200 mg daily for three months.&#xD;
&#xD;
      Group B: Will receive PUVA with dosing &amp; increments according to the standard protocols of&#xD;
      the Phototherapy Unit, Dermatology Department, Cairo University; 3 sessions per week for 3&#xD;
      months.&#xD;
&#xD;
      III. Timings of follow up visits and clinical assessments done:&#xD;
&#xD;
      Patients will be regularly assessed at weeks 4, 8, and 12. Patients continuing for another&#xD;
      three months, as mentioned above, will be assessed at weeks 16, 20 and 24. The following will&#xD;
      be done at these follow up visits: mSWAT, CAILS, pruritus scoring and photography. Side&#xD;
      effects will be monitored and managed accordingly.&#xD;
&#xD;
      IV. Follow up biopsies:&#xD;
&#xD;
      A repeat biopsy will be taken at initial improvement in CAILS (or at week 12) for&#xD;
      immunohistochemical re-assessment of the expression of CD3 and Bcl2 by the lymphocytes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical assessment</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical assessment of the extent of the lesions in body surface area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological assessment</measure>
    <time_frame>3months</time_frame>
    <description>Pathological assessment using immunohistochemistry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Doxycyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phototherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UVA+ psoralen 3 sessions per week for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vibramycin</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Doxycyline</arm_group_label>
    <arm_group_label>Phototherapy</arm_group_label>
    <other_name>Doxy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phototherapy</intervention_name>
    <description>UVA+Psoralen</description>
    <arm_group_label>Doxycyline</arm_group_label>
    <arm_group_label>Phototherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (above 18) of either sex with established diagnosis of classic MF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any variant of MF other than the classic variant.&#xD;
&#xD;
          -  Advanced stages of classic MF: Stage IIb, III or IV.&#xD;
&#xD;
          -  Pregnant and lactating females.&#xD;
&#xD;
          -  Patients with autoimmune diseases e.g. SLE&#xD;
&#xD;
          -  Patients with solid or hematological malignancies e.g. breast cancer, leukemia, etc.&#xD;
&#xD;
          -  Patients with any contraindications for doxycycline (eg: liver disease, kidney&#xD;
             disease, photosensitivity, peptic ulcer or patients receiving systemic retinoids).&#xD;
&#xD;
          -  Patients with any contraindication to phototherapy (eg: any other skin cancers or&#xD;
             photosensitivity); or to psoralen (eg: liver disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona AbdEl Halim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hagar El Sayed, Master</last_name>
    <phone>01061248365</phone>
    <email>hgr_ntr@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzan Shalaby, MD</last_name>
    <phone>01224019459</phone>
    <email>suzyandnls@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dermatology departement</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagar El Sayed, MD</last_name>
      <phone>01051248365</phone>
      <email>hgr_ntr@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Suzan Shalaby, MD</last_name>
      <phone>01224019459</phone>
      <email>suzyandnls@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dermatology department</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagar El Sayed, Master</last_name>
      <phone>01061248365</phone>
      <email>hgr_ntr@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Suzan Shalaby, MD</last_name>
      <phone>01224019459</phone>
      <email>suzyandnls@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hagar El Sayed</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Mycosis fungoides</keyword>
  <keyword>Doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

